Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

FDA endorses alpha-synuclein biomarker for Parkinson’s clinical trials

25

Aug 2026

FDA endorses alpha-synuclein biomarker for Parkinson’s clinical trials

Critical Path Institute® (C-Path) today announced the publication of "Regulatory endorsement for the application of alpha-synuclein seed amplification assay (αSyn-SAA) as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies" in the Journal of Parkinson's Disease, marking a significant milestone for its Critical Path for Parkinson's consortium.

Scientists found a distinct gut microbiome pattern in people with symptomatic diverticular disease

25

Aug 2026

Scientists found a distinct gut microbiome pattern in people with symptomatic diverticular disease

A multicenter Japanese study found that symptomatic uncomplicated diverticular disease (SUDD) was associated with reduced gut microbial diversity, increased abundance of the Ruminococcus gnavus group, and depletion of Coprococcus and other butyrate-producing bacteria. Predictive microbiome analysis also identified enrichment of pathways linked to exopolysaccharide biosynthesis and the cell cycle, although the observational design means these associations cannot establish causality.

A year after women lost weight, researchers saw which health gains lasted and which faded

25

Aug 2026

A year after women lost weight, researchers saw which health gains lasted and which faded

Diet-induced weight loss significantly reduced predicted 10-year risks of major adverse cardiovascular events and type 2 diabetes in healthy premenopausal women with overweight, regardless of whether aerobic or resistance exercise was added. Some of these gains diminished as weight was partially regained over the following year, although greater exercise adherence was associated with less rebound in predicted diabetes risk.

Internalized racial oppression may undermine culturally affirming parenting

25

Aug 2026

Internalized racial oppression may undermine culturally affirming parenting

Black parents who experienced higher levels of appropriated racial oppression - defined as shaping one's behavior and self-concept around dominant cultural norms of whiteness - were less likely to transmit positive, culturally protective messages that affirmed racial pride and self-worth to their adolescent children, a recent study found.

Study reveals how the brain balances competing goals

25

Aug 2026

Study reveals how the brain balances competing goals

How do we decide what to do when faced with choices? And how does the brain adapt those decisions as the world around us changes? A new study published in Nature by researchers at Baylor College of Medicine and Duncan Neurological Research Institute at Texas Children's Hospital offers surprising insights by revealing how the human brain continuously balances competing goals in real time.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.